LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with atrial fibrillation and thromboembolism.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Treatments: Anticoagulants; Warfarin

Criteria

Inclusion Criteria:

• 18-80 years

• Have documented AF episodes

• The occurrence of ischemic stroke, TIA or systemic thromboembolism at least one month before enrollment

• Capable of understanding and signing the CRF

Exclusion Criteria:

• Reversible AF

• Modified Rankin score ≥4

• Having a history of rheumatic, severe valvular heart disease or heart valve replacement

• Having symptomatic carotid artery disease

• Having another disease which requires lifelong warfarin therapy

• Medical conditions limiting expected survival to <1 year

• Women of childbearing potential (unless post-menopausal or surgically sterile)

• Participation in any other clinical mortality trial

• Unable to give informed consent